Evidence map›Paper›PMID 38505512›Full record

ArticleFrontiers in oncology2023

Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report.

Oscar Ramirez, Vivian Piedrahita, Jesus Ardila, Carlos Pardo, Edgar Cabrera-Bernal, John Lopera, Amaranto Suarez, Carlos Andrés Portilla, Carlos Narváez, Pamela Rodriguez and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Addressing population-level cancer data needs in northwestern Mexico: results from a South-South Colombian-Mexican partnership.Revista panamericana de salud publica = Pan American journal of public health · 2025
    Article
  4. Building a transdisciplinary network to improve survival in children with cancer in Colombia: seeds to forests.Revista panamericana de salud publica = Pan American journal of public health · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Oscar RamirezUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Vivian PiedrahitaUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Jesus ArdilaUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Carlos PardoUnidad de Oncología y Hematología Pediátrica, Hospital de la Misericordia (HOMI) Fundación Hospital Pediátrico la Misericordia, Bogotá, Colombia.
Edgar Cabrera-BernalUnidad de Oncología y Hematología Pediátrica, Hospital de la Misericordia (HOMI) Fundación Hospital Pediátrico la Misericordia, Bogotá, Colombia.
John LoperaUnidad de Oncología y Hematología Pediátrica, Instituto Nacional de Cancerología, Bogotá, Colombia.
Amaranto SuarezUnidad de Oncología y Hematología Pediátrica, Instituto Nacional de Cancerología, Bogotá, Colombia.
Carlos Andrés PortillaUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Carlos NarváezUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Pamela RodriguezUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Ximena CastroUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Ángel CastroDepartamento de Pediatría, Universidad de Cartagena, Unidad de Oncología y Hematología Pediátrica, Clínica Blas de Lezo, Cartagena, Colombia.
Diego Ivan Estupinan-PericoUnidad de Oncología y Hematología Pediátrica, Clínica Materno Infantil San Luis, Bucaramanga, Colombia.
Diana ValenciaUnidad de Oncología y Hematología Pediátrica: Instituto Médico de Alta Tecnología (IMAT) Oncomédica, Montería, Colombia.
María Del Rosario ÁlvarezUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Javier Enrique FoxUnidad de Oncología y Hematología Pediátrica, Fundación San Vicente de Paul, Medellín, Colombia.
Luis Eduardo BravoUnidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA), Cali, Colombia.
Paula AristizabalDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of California, San Diego, San Diego, CA, United States.
Universidad del Valle · COFundación Valle del Lili · COInstituto Nacional de Cancerología · COUniversidad Nacional de Colombia · COHospital Universitario de San Vicente Fundación · COOncoMed (United States) · USUniversity of California, San Diego · USUniversity of Cartagena · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities. Methods: We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox's regression, stratified by city and year of diagnosis. Results: During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7-11.8), 6.4 (95% CI, 4.2-9.8), 2.8 (95% 2.1-3.8), 2.0 (95% CI, 1.3-2.8) and 2.3 (95% CI, 1.7-3.0), respectively. Conclusion: We found that half of Colombia's children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.

Indexed as

central nervous system neoplasmschildrenepidemiologyLatin Americapediatricsprognosissurvivaltreatment outcome

Identifiers

PMID38505512
PMCPMC10949889
OpenAlexW4392196468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.